LOC107986092: A Promising Drug Target and Biomarker for Disease
LOC107986092: A Promising Drug Target and Biomarker for Disease
LOC107986092 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its unique sequence has led some researchers to believe that it may have a role in the development and progression of certain diseases. Although more research is needed to fully understand its potential, LOC107986092 has shown promise as a drug target and may be a valuable biomarker for certain conditions.
The protein LOC107986092 is a member of the superfamily of evolutionarily conserved transmembrane protein (SMT), which includes a variety of proteins that play important roles in various cellular processes. SMT proteins are characterized by their ability to span the cell membrane and interact with a wide range of molecules on both sides. This allows them to span the membrane and interact with other proteins, as well as with intracellular signaling molecules, making them useful for a variety of cellular functions.
One of the key features of LOC107986092 is its unique sequence. LOC107986092 has 20 distinct amino acid residues, and its first amino acid residue is a glutamic acid, which is often associated with protein stability. The remaining 19 amino acids in the protein are located at the C-terminus, and they include a variety of conserved structural elements, such as a hydrophobic placeholder and a putative signal sequence.
The unique sequence of LOC107986092 has led some researchers to believe that it may have a role in the development and progression of certain diseases. For example, some studies have suggested that LOC107986092 may be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This is because the protein is often expressed in the brain and has been shown to interact with a variety of intracellular signaling molecules, including the tau protein, which is often associated with the development of these diseases.
In addition to its potential involvement in neurodegenerative diseases, LOC107986092 has also shown promise as a drug target. The protein is known to interact with a variety of small molecules, including inhibitors of the protein kinase CKL, which is a known suppressor of the tau protein. This suggests that LOC107986092 may be a good candidate for drugs that are designed to inhibit the activity of CKL and tau.
Another potential application of LOC107986092 is as a biomarker for certain diseases. The protein is expressed in a variety of tissues and has been shown to be involved in a variety of cellular processes, which makes it a potential candidate for use as a biomarker for certain diseases. For example, some studies have suggested that LOC107986092 may be involved in the development of certain types of cancer, such as melanoma and lung cancer. This is because the protein is often expressed in the cells of cancer cells and has been shown to interact with a variety of signaling molecules, including the TGF-beta protein, which is often involved in the development of these diseases.
Overall, LOC107986092 is a protein that has shown promise as a drug target and may be a valuable biomarker for certain conditions. Further research is needed to fully understand its potential and determine its exact role in the development and progression of disease. However, the unique sequence of LOC107986092 and its interaction with a variety of cellular signaling molecules make it a promising candidate for further study.
Protein Name: Uncharacterized LOC107986092
The "LOC107986092 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC107986092 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC107986115 | LOC107986139 | LOC107986141 | LOC107986142 | LOC107986146 | LOC107986148 | LOC107986166 | LOC107986178 | LOC107986186 | LOC107986195 | LOC107986203 | LOC107986205 | LOC107986215 | LOC107986223 | LOC107986229 | LOC107986257 | LOC107986272 | LOC107986286 | LOC107986291 | LOC107986297 | LOC107986298 | LOC107986300 | LOC107986362 | LOC107986368 | LOC107986385 | LOC107986400 | LOC107986420 | LOC107986429 | LOC107986440 | LOC107986451 | LOC107986452 | LOC107986453 | LOC107986454 | LOC107986469 | LOC107986517 | LOC107986522 | LOC107986528 | LOC107986537 | LOC107986544 | LOC107986545 | LOC107986561 | LOC107986589 | LOC107986594 | LOC107986595 | LOC107986597 | LOC107986598 | LOC107986606 | LOC107986613 | LOC107986622 | LOC107986623 | LOC107986626 | LOC107986636 | LOC107986649 | LOC107986666 | LOC107986764 | LOC107986766 | LOC107986770 | LOC107986771 | LOC107986772 | LOC107986774 | LOC107986776 | LOC107986777 | LOC107986781 | LOC107986787 | LOC107986800 | LOC107986816 | LOC107986820 | LOC107986836 | LOC107986844 | LOC107986873 | LOC107986892 | LOC107986894 | LOC107986901 | LOC107986903 | LOC107986927 | LOC107986930 | LOC107986952 | LOC107986961 | LOC107986983 | LOC107986996 | LOC107987026 | LOC107987045 | LOC107987049 | LOC107987053 | LOC107987057 | LOC107987064 | LOC107987087 | LOC107987099 | LOC107987121 | LOC107987164 | LOC107987178 | LOC107987211 | LOC107987243 | LOC107987249 | LOC107987251 | LOC107987282 | LOC107987285 | LOC107987299 | LOC107987301 | LOC107987304
